<DOC>
	<DOC>NCT00911963</DOC>
	<brief_summary>The purpose of this study is to assess antiviral activity when administered alone for 3 days or in combination with peginterferon and ribavirin for 12 weeks. This study will also evaluate the safety and tolerability of treatment with VCH-222 when given alone or in combination with peginterferon and ribavirin. The study will also evaluate the pharmacokinetic profile of VCH-222 in HCV infected subjects.</brief_summary>
	<brief_title>Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Male and Female subjects, 1865 years of age (females nonchild bearing potential in Part B) Have laboratory evidence of HCV infection for 6 months, defined by (1) presence of antiHCV antibody (Genotype 1a and 1b infection), or (2)documented HCV RNA presence by a sensitive and specific assay and (3 histologic evidence of CHC (Fibrosis on a standardized histological grading system) Plasma HCV RNA of 100,000 IU/ml HIV 1 and HIV2 ab seronegative Body Mass Index (BMI) â‰¤ 35 kg/m2 BMI Treatment Naive subjects Contraindications to peginterferon or ribavirin therapy Have evidence of liver cirrhosis, decompensated liver disease, and ChildPugh score &gt; 5 Have hemoglobinopathies, unstable cardiac disease, history of organ transplant, active malignant disease or uncontrolled Type I or II diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>VX-222</keyword>
</DOC>